Bevacizumab in Treating Patients With Myelodysplastic Syndrome
|ClinicalTrials.gov Identifier: NCT00022048|
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : May 15, 2013
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them.
PURPOSE: This phase I/II trial is to see if bevacizumab works in treating patients who have myelodysplastic syndrome.
|Condition or disease||Intervention/treatment||Phase|
|Leukemia Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasms||Biological: bevacizumab||Phase 1 Phase 2|
- Determine the hematologic responses, including changes in hemoglobin levels, neutrophil counts, platelet counts, and percentage of bone marrow blasts, in patients with myelodysplastic syndrome treated with bevacizumab.
- Determine the toxic effects of this regimen in these patients.
- Determine the tolerance in patients treated with this regimen.
- Determine bone marrow cytogenetic responses in patients treated with this regimen.
- Determine bone marrow microvessel density in patients treated with this regimen.
OUTLINE: This is a multicenter study. Patients are stratified according to International Prognostic Scoring System risk status (low (low or intermediate-1) vs high (intermediate-2 or high)).
Patients receive bevacizumab IV over 30-90 minutes. Treatment repeats every 2 weeks for 4-6 months in the absence of disease progression or unacceptable toxicity.
Patients are followed at weeks 1, 3, 5, 7, and 9.
PROJECTED ACCRUAL: A total of 16-25 patients will be accrued for this study within 2 years.
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||Safety and Efficacy Trial of Bevacizumab: Anti-VEGF Humanized Monoclonal Antibody (NSC 704865) Therapy for Myelodysplastic Syndrome (MDS)|
|Study Start Date :||August 2001|
|Study Completion Date :||November 2004|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00022048
|United States, Arizona|
|Arizona Cancer Center at University of Arizona Health Sciences Center|
|Tucson, Arizona, United States, 85724|
|United States, California|
|Stanford Cancer Center at Stanford University Medical Center|
|Stanford, California, United States, 94305-5750|
|United States, Texas|
|University of Texas - MD Anderson Cancer Center|
|Houston, Texas, United States, 77030-4009|
|Study Chair:||Peter L. Greenberg, MD||Stanford University|